---
canonical_url: https://www.stockexpertai.com/earnings/gl
last_updated: 2026-05-09T16:05:03.951Z
---

# Globe Life Inc. (GL) Q4 FY2026 Earnings Preview

> This content was automatically generated with FMP live data + Q1 FY2026 earnings call transcript. Generated: 2026-05-09T16:05:03.380Z. Educational tool, not investment advice.

---

## Quick Summary

| Field | Value | Source |
|---|---|---|
| Price | $151.08 (▼ -0.90%) | fmp:quote |
| Market Cap | $11.9B | fmp:profile |
| 52w range | $116.73 – $156.69 | fmp:quote |
| Earnings | Wed 22 Jul | fmp:earnings-history |
| EPS estimate | $3.68 (+13% YoY) | fmp:earnings-estimate |
| Revenue estimate | $1.6B | fmp:earnings-estimate |
| Beat streak | 0/4 | fmp:earnings-history |
| Rating | A (overall 4/5) | fmp:ratings |
| Analyst median target | $172 (+13.5% upside) | fmp:price-target-consensus |
| MoonshotScore | 53/100 | derived |
| Council | 3/6 bullish | derived |
| Munger verdict | Fairly Valued | derived |

## Globe Life Inc. — Q4 FY2026 Expectations

Q4 consensus: revenue <strong data-source="fmp:earnings-estimate" data-field="estimates.next.revenueAvgLabel">$1.6B</strong><sup class="cite" data-source="fmp:earnings-estimate" data-field="estimates.next.revenueAvg" title="FMP est">[FMP est]</sup>, EPS <strong data-source="fmp:earnings-estimate" data-field="estimates.next.epsAvg">$3.68</strong><sup class="cite" data-source="fmp:earnings-estimate" data-field="estimates.next.epsAvg" title="FMP est">[FMP est]</sup>. 0 consecutive quarters of beat<sup class="cite" data-source="fmp:earnings-history" data-field="earnings.beatStreakCount" title="FMP earnings">[FMP earnings]</sup>.

## Quick Take

**Score:** A · **Stance:** HOLD · **Council:** 3/6 · **Moonshot:** 53

= MoonshotScore <strong>53</strong><sup class="cite" data-source="derived" data-field="moonshot.score" title="9-pillar formula">[9-pillar formula]</sup> + Council <strong>3/6</strong><sup class="cite" data-source="derived" data-field="council.bullishCount" title="6-lens rule">[6-lens rule]</sup>. Form 4: 0 transactions<sup class="cite" data-source="fmp:insider-trading" data-field="insider.txCount" title="FMP Form 4">[FMP Form 4]</sup>.

## Watchlist (4 metrics)

### 1. Health Premium Growth Guidance

Globe Life expects health premium revenue to grow in the range of 14% to 17% for the year.

> "For the year, we expect health premium revenue to grow in the range of 14% to 17%."
> — Frank Svoboda, Expectation / Guide · Q1 FY2026

### 2. Life Premium Growth Guidance

Globe Life expects life premium revenue to grow between 3% and 3.5% for the year 2026.

> "For the year, we expect life premium revenue to grow between 3% and 3.5%."
> — Frank Svoboda, Expectation / Guide · Q1 FY2026

### 3. Premium Revenue Growth Guidance

Globe Life expects total premium revenue to grow approximately 7% for the full year 2026.

> "For the full year, we expect total premium revenue to grow approximately 7%."
> — Frank Svoboda, Expectation / Guide · Q1 FY2026

### 4. Share Repurchase Increase

Globe Life has increased the range for anticipated share repurchases to $560 million to $610 million for the full year 2026.

> "In addition, we have increased the range for anticipated share repurchases to $560 million to $610 million for the full year."
> — Thomas Kalmbach, Investor Focus · Q1 FY2026


## MoonshotScore Pillars

| Pillar | Score | Level | Evidence |
|---|---|---|---|
| Revenue Growth | 3.0 | weak | Q1 vs Q2: moderate growth (+5.3%) |
| Gross Margin | 5.0 | medium | Q1: average margin (49.4%) |
| Operating Leverage | 2.0 | weak | op margin healthy (23.6%) |
| Cash Runway | 10.0 | strong | FCF very strong ($0.4B, 15.9× CapEx) |
| R&D Intensity | 3.0 | weak | low R&D investment (0.0%, weak innovation) |
| Price Momentum | 7.0 | strong | RSI 54.0 balanced, 50d above |
| News Sentiment | 7.0 | strong | strong buy consensus (73%) |

**Formula:** sum(pillar.score) / (count * 10) * 100. Each pillar deterministic from FMP. Source maps in pillar.formula.

## Council (7-Lens)

| Name | Stance | Context |
|---|---|---|
| Ray Dalio | bull | macro · target upside +13.5% |
| Ken Griffin | bull | flow · 50d MA above |
| Jim Simons | neutral | quant · RSI 54 |
| Klarman | neutral | value · target upside +13.5% |
| Buffett | bull | quality · ROE score 5/5 |
| Munger | neutral | valuation · target upside +13.5% |

**Formula:** Each lens uses deterministic rule on bundle data. Logged in member.contextTr.

## Munger Lens

- **Verdict:** Fairly Valued
- **Financial Health:** Strong
- **Margin of Safety:** Moderate
- **Interest Coverage:** Adequate
- **ROIC vs WACC:** Healthy

**Formula:** verdict=upside>25?Undervalued:>0?Fairly Valued:Overvalued. Each lens deterministic from FMP ratings + priceTarget.

## Technical Levels

- **RSI(14):** 54.0 — dengeli — yön sinyali zayıf
- **50d MA:** $145 — hisse %3.9 üstünde — kısa vadeli destek
- **200d MA:** $140 — hisse %7.7 üstünde — uzun vadeli destek
- **Volume (10d):** -10%

## Past Performance (4 Quarters)

| Quarter | EPS Actual | EPS Estimate | Result | Reaction |
|---|---|---|---|---|
| Q2 FY25 | $3.27 | $3.25 | BEAT | +5.4% |
| Q3 FY25 | $4.81 | $4.60 | BEAT | +0.1% |
| Q4 FY25 | $3.39 | $3.44 | MISS | +1.5% |
| Q1 FY26 | $3.43 | $3.46 | +-0.9% EPS | +1.8% |

Q1 (April 23, 2026): EPS $3.43 vs $3.46 est<sup class="cite" data-source="fmp:earnings-history" data-field="earnings.history.0" title="FMP">[FMP]</sup>, +-0.9% beat. D+1 movement: +1.8%<sup class="cite" data-source="fmp:earnings-history" data-field="earnings.timeline.3.reactionLabel" title="FMP D+1">[FMP D+1]</sup>. Decline despite beat — market reacted to guidance, not numbers.

## 3 Scenarios

### Scenario A · Beat
**Q4 EPS > $3.68 + CapEx discipline**

Threshold: EPS > $3.68<sup class="cite" data-source="fmp:earnings-estimate" data-field="estimates.next.epsAvg">[FMP est]</sup>.

Target: Break above median target $172<sup class="cite" data-source="fmp:price-target-consensus" data-field="priceTarget.median">[FMP target]</sup>; high target $185<sup class="cite" data-source="fmp:price-target-consensus" data-field="priceTarget.high">[FMP]</sup> upper bound.

### Scenario B · In-Line
**EPS ≈ $3.68 + CapEx < $24.9M**

Threshold: EPS ≈ $3.68<sup class="cite" data-source="fmp:earnings-estimate" data-field="estimates.next.epsAvg">[FMP est]</sup>, Q4 CapEx < $24.9M<sup class="cite" data-source="fmp:cashflow" data-field="cashflow.qPrev.capexLabel">[FMP]</sup>.

Target: Consolidation in the band between current $151<sup class="cite" data-source="fmp:quote" data-field="quote.price">[FMP]</sup> and median $172<sup class="cite" data-source="fmp:price-target-consensus" data-field="priceTarget.median">[FMP]</sup>.

### Scenario C · Miss
**EPS < $3.57 or CapEx ≥ $24.9M**

Threshold: EPS < $3.57<sup class="cite" data-source="fmp:earnings-estimate" data-field="estimates.next.epsAvg">[FMP est×0.97]</sup>.

Target: Current $151 below SMA200 $140<sup class="cite" data-source="fmp:technical" data-field="technical.sma200">[FMP]</sup>, if rejection continues, $119<sup class="cite" data-source="derived" data-field="technical.sma200" data-formula="round(sma200*0.85)">[derived]</sup> support activates.

## Risk Notes

### Primary segment below threshold
Q1: EPS $3.43 vs $3.46 beat<sup class="cite" data-source="fmp:earnings-history" data-field="earnings.history.0" title="FMP">[FMP]</sup>, stock +1.8% D+1<sup class="cite" data-source="fmp:earnings-history" data-field="earnings.timeline.3.reactionLabel" title="FMP">[FMP]</sup>.

### Backlog concentration
No RPO/backlog concentration disclosed in Q1 earnings call.

### Insider trading
Form 4 data is marked in the table — this page does not generate assumptions for this stock.

| Executive | Action | Amount | Date |
|---|---|---|---|


**Net:** — (0 transactions · 0 sells · 0 buys) · Q1 FY26

### CapEx shock
Q1 CapEx $24.9M<sup class="cite" data-source="fmp:cashflow" data-field="cashflow.qPrev.capexLabel" title="FMP cashflow">[FMP cashflow]</sup>. Q1 op margin 23.6%<sup class="cite" data-source="fmp:income" data-field="income.quarters.0.operatingMargin" title="FMP op margin">[FMP op margin]</sup> — this level in Q4 is sensitive to CapEx revision risk.

## Wall Street Consensus

- **Median target:** $172 (+13.5% upside vs current $151)
- **High / Low:** $185 / $157
- **Buy / Hold / Sell:** 8 / 3 / 0
- **Analyst count:** 2 (last quarter), 27 all-time

## Additional Transcript Insights

### 1. premium_revenue_growth_guidance

**Claim:** Globe Life expects total premium revenue to grow approximately 7% for the full year 2026.

**Evidence (transcript):** "For the full year, we expect total premium revenue to grow approximately 7%."

**Numbers:** 7%

### 2. life_premium_growth_guidance

**Claim:** Globe Life expects life premium revenue to grow between 3% and 3.5% for the year 2026.

**Evidence (transcript):** "For the year, we expect life premium revenue to grow between 3% and 3.5%."

**Numbers:** 3%, 3.5%

### 3. health_premium_growth_guidance

**Claim:** Globe Life expects health premium revenue to grow in the range of 14% to 17% for the year.

**Evidence (transcript):** "For the year, we expect health premium revenue to grow in the range of 14% to 17%."

**Numbers:** 14%, 17%

### 4. admin_expense_ai_impact

**Claim:** Globe Life believes that expanded implementation of AI applications across the company will help drive this ratio lower over the long term.

**Evidence (transcript):** "Over the long term, we anticipate that expanded implementation of AI applications across the company will help drive this ratio lower."

**Numbers:** —

### 5. agent_count_growth_strategy

**Claim:** Globe Life has implemented compensation adjustments for its middle management team that is designed to emphasize new agent recruiting and retention of new agents, and it is expected to have a positive impact on our overall agent count during the second half of this year.

**Evidence (transcript):** "As we discussed in the last call, at the beginning of the second quarter, we have implemented compensation adjustments for our middle management team that is designed to emphasize new agent recruiting and retention of new agents."

**Numbers:** —

### 6. share_repurchase_increase

**Claim:** Globe Life has increased the range for anticipated share repurchases to $560 million to $610 million for the full year 2026.

**Evidence (transcript):** "In addition, we have increased the range for anticipated share repurchases to $560 million to $610 million for the full year."

**Numbers:** $560 million, $610 million


---

*Data source: FMP (live query, 2026-05-09), Q1 FY2026 earnings call transcript (Translated to EN with Gemini 2.0 Flash). Educational tool, not investment advice.*